A phase II study of intermittent Gleevec (imatinib mesylate) and weekly paclitaxel in patients aged 70 or older with advanced non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2015
At a glance
- Drugs Imatinib (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Jul 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 24 Jul 2012 Status changed from `active, no longer recruiting' to `discontinued' as reported by ClinicalTrials.gov.
- 20 Oct 2011 Planned End Date changed from 1 Aug 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov (NCT01011075).